Success Metrics

Clinical Success Rate
66.7%

Based on 6 completed trials

Completion Rate
67%(6/9)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
3(27%)

Phase Distribution

Ph phase_3
1
9%
Ph phase_4
1
9%
Ph not_applicable
2
18%
Ph phase_1
4
36%
Ph phase_2
1
9%

Phase Distribution

4

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
1(11.1%)
Phase 3Large-scale testing
1(11.1%)
Phase 4Post-market surveillance
1(11.1%)
N/ANon-phased studies
2(22.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

6 of 9 finished

Non-Completion Rate

33.3%

3 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(6)
Terminated(3)
Other(2)

Detailed Status

Completed6
Terminated3
unknown2

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (44.4%)
Phase 21 (11.1%)
Phase 31 (11.1%)
Phase 41 (11.1%)
N/A2 (22.2%)

Trials by Status

unknown218%
completed655%
terminated327%

Recent Activity

Clinical Trials (11)

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
11